SPT · Sprout Social, Inc · Stock research

Current Thesis

The leg on offer is a margin-inflection re-rate on a low-growth social-management SaaS. On 2026-08-06 the company raised FY2026 non-GAAP EPS guidance to $1.11–1.15 from $0.88–0.97 (consensus $0.92) while moving the FY revenue range only from $492.5–495.5M to $493.0–495.6M. What is being bought is operating leverage and cash conversion on an 11%-growth revenue line, plus the first buyback in the company's history. What is not being bought is a growth acceleration — the Q3 revenue guide of $123.3–124.1M straddles the $123.847M Q2 actual.

Bullish and bearish views on Sprout Social, Inc

The model's bull view on Sprout Social, Inc (SPT), in brief: 2026-08-06 print beat on the profit line, not the top line by much: Q2 non-GAAP EPS $0.26 against $0.16 consensus; revenue $123.847M against $122.111M consensus. The bear view: Growth is 11% and the Q2 release did nothing to change it. Both cases follow in full.

Bull Case

• 2026-08-06 print beat on the profit line, not the top line by much: Q2 non-GAAP EPS $0.26 against $0.16 consensus; revenue $123.847M against $122.111M consensus. Non-GAAP operating income $16.0M on $123.8M of revenue.
• The guidance raise was large and specific: FY2026 non-GAAP operating income guided $68.3–70.3M; Q3 non-GAAP operating income $17.5–18.3M and non-GAAP EPS $0.29–0.30 versus $0.24 consensus.
• Enterprise mix is compounding faster than the company: trailing-twelve-month subscription revenue from customers at or above $30K ARR reached $291.7M as of 2026-06-30, 61.4% of subscription revenue, up 20% YoY. Customers at or above $50K ARR numbered 2,127, up 16% YoY.
• Cash conversion turned: Q2 non-GAAP free cash flow $8.3M, roughly 60% higher YoY, with trailing-twelve-month free cash flow around $54M. Cash and equivalents $119.9M at 2026-06-30.
• Capital return started: the board authorized up to $50M of Class A repurchases on 2026-05-07, the company's first. Management framed it as a response to a gap between the share price and its own valuation view.
• Estimate revisions ran one direction after the print: KeyBanc to $7 on 2026-08-07, Barclays to $12 on 2026-08-11, Morgan Stanley to $11 on 2026-08-13 — three raises inside a week, including from the most bearish desk.

Bear Case

• Growth is 11% and the Q2 release did nothing to change it. Q2 revenue grew 11% YoY; Q1 2026 grew 11% as well. The FY2026 range implies the same shape through year-end.
• The Q3 revenue guide brackets flat sequentially. $123.3–124.1M against a Q2 actual of $123.847M, and against $123.647M consensus. Sequential revenue growth is guided to roughly nothing.
• New logos are thin. 51 net adds in the ≥$30K ARR cohort during Q2, 388 over the trailing twelve months, and cohort count growth of 11% against 20% cohort revenue growth. The revenue is coming from existing accounts spending more, which is a slower-decaying but capped source.
• The headline number is non-GAAP. GAAP operating loss was $2.7M in Q2 2026 while non-GAAP operating income was $16.0M. The $1.11–1.15 FY figure is not a GAAP earnings stream.
• The sell-side disagrees violently. KeyBanc's Underweight target of $7 (2026-08-07) sits far below the 2026-08-21 close of $10.02; Barclays' Overweight target of $12 (2026-08-11) sits above it. The spread is the argument over whether an 11% grower earns any multiple expansion for margin alone.
• Platform dependency is structural. The product is built on third-party APIs at Meta, X, LinkedIn, TikTok and YouTube. Access terms and pricing are set elsewhere.

Setup & Price Structure

• Reference close $10.02 on 2026-08-21. 52-week high $15.83, leaving the shares 36.7% below it. Three-month price change of +46.9%.
• RSI(14) at 64.4 — extended, short of an overbought extreme.
• Most of the move came after the print, not on it. Post-print coverage on 2026-08-06 cited the shares up 4.3% near $8.53. The advance to $10.02 accumulated over the following two weeks, alongside the 08-07 / 08-11 / 08-13 target revisions. Continuation buying after a small print reaction is expanding participation, which is what dates this leg as ACCELERATING rather than MATURING.
• Price has travelled into the published target band. The two most recent targets, $11 and $12, sit roughly 10–20% above the 2026-08-21 close. Further sell-side lift requires new targets, not new coverage of old ones.
• The structural shelf is the pre-print range around $8.50, where the post-2026-08-06 advance originated.
• Crowding observables: no earnings date inside the next 30 days; no filings in the recent record; the $50M authorization announced 2026-05-07 was not accompanied by a disclosed repurchase amount in the Q2 earnings materials. There is no insider-selling or issuance-into-strength datapoint in the available record to cite either way — absence of evidence, not evidence of absence.

Catalyst Calendar (next 30 days)

• 2026-08-22 to 2026-09-21 — no confirmed company event. The window is empty of scheduled catalysts. Q2 landed 2026-08-06; the next scheduled disclosure is a quarter away.
• 2026-09-18 — September quarterly options expiration and index rebalance. A flow date rather than an information date, and the only dated market event in the window for a name this size.
• ~2026-11-05 (est.) — Q3 2026 results. Date unconfirmed by the company. This marks the $123.3–124.1M revenue guide, the $0.29–0.30 non-GAAP EPS guide, and whether the FY2026 revenue range survives intact.
• ~2026-11-05 (est.) — Q3 2026 10-Q. First document in which a repurchase figure under the 2026-05-07 $50M authorization would appear for the September quarter.

What Would Change Our Mind

The fundamental break is a Q3 revenue print at or below the $123.3M guide floor, or an FY2026 revenue-range cut at the early-November report. The whole re-rate rests on the claim that 11% growth is durable while operating income expands; margin is a cost line and stops compounding once the cuts are lapped, so a revenue disappointment removes the only part of the story that persists past FY2026.

On price, the gradeable condition is a weekly close below $8.50 — that erases the entire post-2026-08-06 advance and returns the shares to the range they held before the print.

A second, slower failure mode: if 2026-09-21 arrives with no new dated catalyst, no new target above $12, and the shares still pinned near $10, the leg has moved from ACCELERATING to MATURING without any price break at all, and the case for new money thins on flow rather than on fundamentals.

What would strengthen the read instead: Q3 net adds in the ≥$30K ARR cohort well above the 51 posted in Q2, or a Q3 10-Q showing a meaningful share of the $50M authorization actually spent.

Correlation Notes

• Beaten-down profitable-pivot SaaS cohort. On 2026-07-27 Benzinga listed SPT alongside ASAN in the same set of movers; the two trade on the same question of whether low-growth software can re-rate on margin.
• Peer read-throughs: HUBS, SEMR, ZI and BRZE. Any of them flagging net revenue retention deterioration marks the expansion assumption that carries SPT's 20% cohort revenue growth against 11% cohort count growth.
• Platform exposure: META, PINS, SNAP and RDDT developer-terms or API-pricing announcements hit the input side of the product directly.
• Beta: small-cap software flow (IGV, IWM). At a 36.7% discount to the 52-week high with a +46.9% three-month move, the name carries high beta to any risk-appetite reversal in unprofitable-to-profitable software.